Emerald Mutual Fund Advisers Trust’s Travere Therapeutics TVTX Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.1M	Sell	945,033 -3,426	-0.4%	-$102K	1.36%	15
2025 Q4	$36.2M	Sell	948,459 -252,483	-21%	-$8.21M	1.77%	7
2025 Q3	$28.7M	Buy	1,200,942 +59,514	+5%	+$1.12M	1.48%	14
2025 Q2	$16.9M	Buy	1,141,428 +19,542	+2%	+$324K	1.03%	30
2025 Q1	$20.1M	Buy	1,121,886 +20,112	+2%	+$408K	1.43%	19
2024 Q4	$19.2M	Sell	1,101,774 -83,935	-7%	-$1.48M	1.17%	29
2024 Q3	$16.6M	Buy	1,185,709 +244,444	+26%	+$2.55M	0.86%	47
2024 Q2	$7.74M	Sell	941,265 -387,116	-29%	-$2.61M	0.41%	85
2024 Q1	$10.2M	Buy	1,328,381 +563,778	+74%	+$4.76M	0.53%	79
2023 Q4	$6.87M	Hold	764,603	–	–	0.36%	97
2023 Q3	$6.84M	Buy	764,603 +235,085	+44%	+$3.32M	0.41%	95
2023 Q2	$8.13M	Buy	+529,518	New	+$9.63M	0.44%	89

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's TVTX Position: Q1 2026 in Review

Emerald Mutual Fund Advisers Trust reduced its Travere Therapeutics (TVTX) stake by 0.36% in Q1 2026, selling an estimated $102K and leaving 945,033 shares worth $28.1M. The position accounts for 1.36% of the portfolio, ranked #15.

Emerald Mutual Fund Advisers Trust first reported a position in TVTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $36.2M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Emerald Mutual Fund Advisers Trust held 945,033 shares of Travere Therapeutics worth $28.1M as of Q1 2026.
Emerald Mutual Fund Advisers Trust sold 3,426 Travere Therapeutics shares in Q1 2026, an estimated $102K.
Travere Therapeutics made up 1.36% of Emerald Mutual Fund Advisers Trust's portfolio in Q1 2026, its #15 holding.
Emerald Mutual Fund Advisers Trust first reported a position in Travere Therapeutics in Q2 2023 and has held it in 12 quarters since.
Emerald Mutual Fund Advisers Trust's Travere Therapeutics position peaked at $36.2M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2026, filed 4 May 2026.